Awadhesh Kumar Singh

Awadhesh Kumar Singh

Auto-generated profile, based on publicly available information

Awadhesh Kumar Singh

Department of Diabetes & Endocrinology GD Hospital & Diabetes Institute Kolkata India

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
Verified
Journal Article
Closed access
ASAwadhesh Kumar Singh
Awadhesh Kumar Singh
RSRitu Singh
Ritu Singh
SJShashank R. Joshi
Shashank R. Joshi
AMAnoop Misra
Anoop Misra

1 July 2020 in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
Verified
Journal Article
Closed access
ASAwadhesh Kumar Singh
Awadhesh Kumar Singh
RGRitesh Gupta
Ritesh Gupta
AGAmerta Ghosh
Amerta Ghosh
AMAnoop Misra
Anoop Misra

23 June 2020 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
PDF file
ASAwadhesh K. Singh
Awadhesh K. Singh
CGClare L. Gillies
Clare L. Gillies
RSRitu Singh
Ritu Singh
ASAkriti Singh
Akriti Singh
YCYogini Chudasama
Yogini Chudasama
KKKamlesh Khunti
Kamlesh Khunti
Aim: To estimate the prevalence of both cardiometabolic and other co‐morbidities in patients with COVID‐19, and to estimate the increased risk of severity of disease and mortality in people with co‐morbidities. Materials and Methods: Medline, Scopus and the World Health Organization website were searched for global research on COVID‐19 conducted from January 2019 up to 23 April 2020. Study inclusion was restricted to English language publications, original articles that reported the prevalence of co‐morbidities in individuals with COVID‐19, and case series including more than 10 patients. Eighteen studies were selected for inclusion. Data were analysed using random effects meta‐analysis models. Results: Eighteen studies with a total of 14 558 individuals were identified. The pooled prevalence for co‐morbidities in patients with COVID‐19 disease was 22.9% (95% CI: 15.8 to 29.9) for hypertension, 11.5% (9.7 to 13.4) for diabetes, and 9.7% (6.8 to 12.6) for cardiovascular disease (CVD). For chronic obstructive pulmonary disease (COPD), chronic kidney disease (CKD), cerebrovascular disease and cancer, the pooled prevalences were all less than 4%. With the exception of cerebrovascular disease, all the other co‐morbidities presented a significantly increased risk for having severe COVID‐19. In addition, the risk of mortality was significantly increased in individuals with CVD, COPD, CKD, cerebrovascular disease and cancer. Conclusions: In individuals with COVID‐19, the presence of co‐morbidities (both cardiometabolic and other) is associated with a higher risk of severe COVID‐19 and mortality. These findings have important implications for public health with regard to risk stratification and future planning.

1 May 2020 in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
Verified
Journal Article
Closed access
ASAwadhesh Kumar Singh
Awadhesh Kumar Singh
ASAkriti Singh
Akriti Singh
ASAltamash Shaikh
Altamash Shaikh
RSRitu Singh
Ritu Singh
AMAnoop Misra
Anoop Misra

30 October 2021 in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
Verified
Journal Article
Closed access
ASAwadhesh Kumar Singh
Awadhesh Kumar Singh
ASAkriti Singh
Akriti Singh
RSRitu Singh
Ritu Singh
AMAnoop Misra
Anoop Misra

1 September 2020 in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
Verified
Journal Article
Closed access
ASAwadhesh Kumar Singh
Awadhesh Kumar Singh
SMSujoy Majumdar
Sujoy Majumdar
RSRitu Singh
Ritu Singh
AMAnoop Misra
Anoop Misra